Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates deep learning-based predictive models, molecular simulations, and molecular generative AI. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022) and Genentech (signed in 2020). Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. We are rapidly growing our team with a variety of openings on our machine learning, computational chemistry, and software teams (primarily located in the Bay Area) and our chemistry, biology, and clinical teams (primarily located in San Diego). To learn more about Genesis Therapeutics, or current employment opportunities, please visit our website.